Q4 EPS Estimates for OTCMKTS:BSEM Boosted by Zacks Small Cap

BioStem Technologies, Inc. (OTCMKTS:BSEM) – Equities researchers at Zacks Small Cap raised their Q4 2024 earnings estimates for BioStem Technologies in a report released on Friday, November 15th. Zacks Small Cap analyst B. Sorensen now expects that the company will post earnings per share of $0.37 for the quarter, up from their previous forecast of $0.32. The consensus estimate for BioStem Technologies’ current full-year earnings is $1.13 per share. Zacks Small Cap also issued estimates for BioStem Technologies’ Q1 2026 earnings at $0.52 EPS, Q2 2026 earnings at $0.57 EPS, Q3 2026 earnings at $0.61 EPS and FY2026 earnings at $2.39 EPS.

BioStem Technologies (OTCMKTS:BSEM) last announced its earnings results on Tuesday, November 12th. The company reported 0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of 0.31 by 0.01. The business had revenue of 82.56 million during the quarter, compared to analyst estimates of 78.22 million.

BioStem Technologies Stock Performance

Shares of BioStem Technologies stock opened at 12.70 on Monday. BioStem Technologies has a 1 year low of 2.34 and a 1 year high of 28.26. The firm’s 50-day simple moving average is 13.60 and its 200-day simple moving average is 10.77. The firm has a market cap of $211.07 million, a PE ratio of 18.68 and a beta of -0.36.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.